search
Back to results

Light Treatment for Scleroderma Finger Ulcers (DULight)

Primary Purpose

Scleroderma, Systemic, Ulcer

Status
Completed
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Custom-built phototherapy lamp
Sponsored by
University of Manchester
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Scleroderma, Systemic focused on measuring Phototherapy

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Participants with a confirmed diagnosis of SSc.
  • Eighteen years of age or older at the time of recruitment.
  • Able to give full informed consent.
  • An active digital ulcer on any aspect of the finger/s (e.g. digital-tip or extensor)

Exclusion Criteria:

  • Unable to give full informed consent.
  • Serious infection of the digital ulcer e.g. osteomyelitis.

Sites / Locations

  • Salford Royal NHS Foundation Trust

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Custom-built phototherapy lamp

Arm Description

Custom-built phototherapy lamp: All participants will receive light treatment twice weekly for three weeks (or until ulcer/s healing) to one or both hands (both hands if ulcer/s present bilaterally). The participant will place their hand within the treatment area of the light-based device (total treatment area approximately 15cm2), aiming to centralise the digital ulcer/s to the centre of the treatment region. At each treatment study visit (visits 1-6 inclusive), the device will undergo a period of (automatic) calibration before use. All three wavelengths (red, infrared and blue) will be delivered simultaneously in combination, with the fluence of the device set at [3J/cm2] (treatment duration approximately 10 to 15 minutes).

Outcomes

Primary Outcome Measures

Number of participants with adverse events as a measure of safety measured by the patient and operator opinion
Number of participants with adverse events as a measure of tolerability measured by the patient opinion

Secondary Outcome Measures

Digital ulcer severity: participant and operator reported
Up to 8 weeks
High-frequency ultrasound (HFUS) to measure digital ulcer dimensions
Up to 8 weeks
Laser Doppler imaging (LDI) to measure perfusion to the digital ulcer

Full Information

First Posted
January 23, 2015
Last Updated
May 6, 2016
Sponsor
University of Manchester
search

1. Study Identification

Unique Protocol Identification Number
NCT02472743
Brief Title
Light Treatment for Scleroderma Finger Ulcers
Acronym
DULight
Official Title
Light-based Therapy as a Novel Treatment for Digital Ulcers in Patients With Systemic Sclerosis
Study Type
Interventional

2. Study Status

Record Verification Date
May 2016
Overall Recruitment Status
Completed
Study Start Date
December 2014 (undefined)
Primary Completion Date
January 2016 (Actual)
Study Completion Date
May 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Manchester

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Digital (finger) ulcers are common in patients with systemic sclerosis (SSc) and causes much pain and affects how patients use their hands. Our current treatments for digital ulcers are often not effective and have may have significant side effects (because they increase blood flow to the ulcer to try and help healing). Light-based treatment has been successfully used to treat chronic diabetic, pressure and venous ulcers. The investigators wish to investigate whether light-based treatment is a safe and effective treatment for digital ulcers in patients with SSc.
Detailed Description
Study design This is an open pilot study: all participants will receive the light-based treatment (visits 1-6 inclusive). Ten participants with at least one digital ulcer (more than one digital ulcer may be assessed in the study if located on the same hand) will be recruited. Justification of sample size There are no pilot data to inform a power calculation. Paired measurements on 10 participants gives 90% power to detect a clinically meaningful change in VAS of 2 points at the 5% significance level, provided that the observed standard deviation in paired differences is 1.7 or less. If the observed standard deviation is 2.0, this sample size gives 80% power to detect such a change at the stated significance level. Methods of data collection Study visits schedule Participants will attend a total of 8 study visits over two months. Light treatment will be administered twice weekly for three weeks (i.e. the first 6 study visits only). Follow-up visits will be at 1 month (visit 7) and 2 months (visit 8). Preparation Participants will be asked to abstain from caffeine-containing drinks and from smoking for at least 4 hours prior to study. Sterile gauze and/or water may be used by the investigators (using gloves) to clean the surface of the wound of any debris that could potentially interfere with the light-based treatment. Application of the light-based device to the digital ulcer Both the participant and investigators will wear appropriate safety goggles (as advised by Medical Physics at Salford Royal NHS Foundation Trust [SRFT]) at all times whilst the light-based device is in operation. The participant will place their hand within the treatment area of the light-based device (total treatment area approximately 15cm2), aiming to centralise the digital ulcer/s to the centre of the treatment region. The device will be controlled by a custom-built computer interface. At each study visit, the device will undergo a period of (automatic) calibration before use. All three wavelengths (red, infrared and blue) will be delivered simultaneously in combination, with the fluence of the device set at [3J/cm2] (treatment duration approximately 10 to 15 minutes). Performance data on the light-based treatment (including the total dose delivered and the performance of the LEDs will be recorded. In the event of catastrophic failure of the device (e.g. failure of multiple LEDs), the device will automatically shut down. Participant and investigator assessment of feasibility Participant and the investigators opinion of the feasibility of light-based treatment will be recorded (at the end of the first and last treatment study visit). Participant and investigator assessment of tolerability Participant and investigator opinion of the tolerability of light-based treatment will be recorded (at the end of the first and last treatment study visit). Participant and investigator opinion Participant and investigator global assessments of the digital ulcer will be performed on a visual analogue scale (0-10, 10 being most severe) at each study visit. A clinical photograph (see immediately below) will be independently scored at a later date by another investigator. Clinical Photography The Clinical Photography department at SRFT will take a photograph of the digital ulcer/s at the end of each study visit. High-frequency ultrasound (HFUS) Will be performed immediately by the investigator after the light-treatment has been delivered and at the follow up visits. The investigator will perform two 'scans' along the short and long axis of the ulcer and use these to make measurements (basal and superficial width/length and volume). Laser Doppler imaging (LDI) Will be performed by the investigator immediately before and directly after treatment (at the digital ulcer site and the corresponding contralateral arm position) at all visits to measure ulcer perfusion.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Scleroderma, Systemic, Ulcer
Keywords
Phototherapy

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
10 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Custom-built phototherapy lamp
Arm Type
Experimental
Arm Description
Custom-built phototherapy lamp: All participants will receive light treatment twice weekly for three weeks (or until ulcer/s healing) to one or both hands (both hands if ulcer/s present bilaterally). The participant will place their hand within the treatment area of the light-based device (total treatment area approximately 15cm2), aiming to centralise the digital ulcer/s to the centre of the treatment region. At each treatment study visit (visits 1-6 inclusive), the device will undergo a period of (automatic) calibration before use. All three wavelengths (red, infrared and blue) will be delivered simultaneously in combination, with the fluence of the device set at [3J/cm2] (treatment duration approximately 10 to 15 minutes).
Intervention Type
Device
Intervention Name(s)
Custom-built phototherapy lamp
Other Intervention Name(s)
N/A: Custom built in house
Intervention Description
Described in the arm description
Primary Outcome Measure Information:
Title
Number of participants with adverse events as a measure of safety measured by the patient and operator opinion
Time Frame
Up to three weeks
Title
Number of participants with adverse events as a measure of tolerability measured by the patient opinion
Time Frame
Up to three weeks
Secondary Outcome Measure Information:
Title
Digital ulcer severity: participant and operator reported
Description
Up to 8 weeks
Time Frame
Up to 8 weeks
Title
High-frequency ultrasound (HFUS) to measure digital ulcer dimensions
Description
Up to 8 weeks
Time Frame
Up to 8 weeks
Title
Laser Doppler imaging (LDI) to measure perfusion to the digital ulcer
Time Frame
Up to 8 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Participants with a confirmed diagnosis of SSc. Eighteen years of age or older at the time of recruitment. Able to give full informed consent. An active digital ulcer on any aspect of the finger/s (e.g. digital-tip or extensor) Exclusion Criteria: Unable to give full informed consent. Serious infection of the digital ulcer e.g. osteomyelitis.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michael Hughes, MSc MRCP
Organizational Affiliation
The University of Manchester
Official's Role
Principal Investigator
Facility Information:
Facility Name
Salford Royal NHS Foundation Trust
City
Manchester
ZIP/Postal Code
M6 8HD
Country
United Kingdom

12. IPD Sharing Statement

Learn more about this trial

Light Treatment for Scleroderma Finger Ulcers

We'll reach out to this number within 24 hrs